A patient support program has been established to transition patients to Egrifta WR, which will gradually replace Egrifta SV. Egrifta WR™, a new concentrated formulation (F8) of tesamorelin, is now ...
(RTTNews) - Theratechnologies Inc. (THTX, TH.TO) announced the availability of EGRIFTA WR (tesamorelin) for injection, approved earlier this year by the U.S. Food and Drug Administration, for the ...
According to Theratechnologies, Egrifta WR is set to replace Egrifta SV. The Food and Drug Administration (FDA) has approved Egrifta WR ™, a new concentrated formulation (F8) of tesamorelin, for the ...
MONTREAL, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage ...
Theratechnologies Receives FDA Approval for EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy On March 25, 2025, the Company announced that the U ...
Tesamorelin 2mg; per vial; lyophilized pwd for SC inj after reconstitution; preservative-free; contains mannitol. Store at room temperature at 20°C to 25°C (68°F to 77°F) in the original box to ...
MONTREAL, April 08, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that ...
MONTREAL, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a specialty biopharmaceutical company focused on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results